OR9L1P

Across TCGA pan-cancer cohorts, OR9L1P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated OR9L1P data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR9L1P RNA is associated with better overall survival. In most high-consensus cancer types, elevated OR9L1P expression acts as an unfavorable survival marker, although some lineages such as OV and KIRC show a favorable association.

OV, KIRC, and THCA are the cancer types where OR9L1P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	All	0.616	0.311	.021	54	view →
KIRC	DFS	Tertile	IV	1.000	0.525	.023	24	view →
THCA	DFS	Tertile	IV	0.514	0.885	<.001	18	view →
LGG	OS	Tertile	All	0.741	0.911	.001	12	view →
LUSC	DFS	Tertile	All	0.694	0.373	.014	6	view →
SKCM	OS	Tertile	All	0.211	0.333	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR9L1P–OV (OS)

Open the OV breakdown →